<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Download Champions' latest AACR 2024 Poster

An Innovative PDX and Patient-derived 3D Platform for Improved Translatability of New Medical Entities 

 

TumorGraft3D Poster 4258 AACR_28Mar2024.pdf

 

Recent advances in preclinical research have significantly improved our ability to understand cancer and test potential therapies. Patient-derived 3D cultures offer a more accurate representation of tumor biology than traditional 2D systems, with their ability to predict clinical drug efficacy depending on the retention of the original tumor’s molecular and histological features. These models provide higher throughput and faster results compared to in-vivo studies. Champions Oncology has developed Champions TumorGraft3D (CTG3D), an innovative ex-vivo platform utilizing over 1500 patient-derived xenografts (PDXs) across 50 tumor types, enabling in-depth molecular and pharmacological characterization of cancers for improved therapeutic testing.

  • Patient-derived 3D cultures better replicate tumor biology and provide faster, high-throughput drug testing compared to 2D models.

  • Drug efficacy prediction depends on maintaining the molecular and histological integrity of the original tumor.

  • Champions Oncology’s CTG3D platform utilizes a large bank of PDXs, enabling detailed molecular and pharmacological characterizations of tumors.



 

Download the Poster